Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 4 802 M
EBIT 2017 1 031 M
Net income 2017 346 M
Debt 2017 2 884 M
Yield 2017 0,83%
Sales 2018 5 020 M
EBIT 2018 1 130 M
Net income 2018 550 M
Debt 2018 2 440 M
Yield 2018 0,97%
P/E ratio 2017 28,87
P/E ratio 2018 18,24
EV / Sales2017 2,69x
EV / Sales2018 2,48x
Capitalization 10 031 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
07/20Shareholder meeting
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
05/24 PERRIGO COMPANY PLC : ex-dividend day
05/23 PERRIGO CO PLC : Other Events (form 8-K)
05/23 PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
05/23 PERRIGO COMPANY PLC (NYSE : PRGO) reported earnings of $1.24 per share missing W..
05/23 PERRIGO : reports 4Q loss
05/22 PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
05/22 PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
05/22 PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
05/15DJDAVID EINHORN : Einhorn's Greenlight Capital Cuts Apple Stake, Confirms Perrigo ..
05/11 PERRIGO ALERT : J&W Investigates Perrigo Company plc after U.S. Department of Ju..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 16
Average target price 78,6 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John T. Hendrickson Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY10 031
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results